Who are PPI, amoxicillin, metronidazole and clarithromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PPI-amoxicillin-clarithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ppi-amoxicillin-metronidazole-and-clarithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PPI, amoxicillin, metronidazole and clarithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PPI, amoxicillin, metronidazole and clarithromycin (PPI, amoxicillin, metronidazole and clarithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy with acid suppression. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy with acid suppression Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

PPI, amoxicillin, metronidazole and clarithromycin (PPI, amoxicillin, metronidazole and clarithromycin) — Infante, Javier Molina, M.D.. This is a quadruple therapy regimen that eradicates Helicobacter pylori by combining acid suppression with three antibiotics that target bacterial protein synthesis and DNA.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PPI, amoxicillin, metronidazole and clarithromycin TARGET	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis
PPI-amoxicillin-clarithromycin	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy with acid suppression class)

Infante, Javier Molina, M.D. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PPI, amoxicillin, metronidazole and clarithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/ppi-amoxicillin-metronidazole-and-clarithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab